High rates of overall response and MRD negativity were seen regardless of the dose patients received, said Andrew Spencer, MBBS.
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...
clinicaltrialsarena on MSN20h
GSK reports positive outcomes from Phase III multiple myeloma treatment trialGSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...
GlobalData on MSN21h
EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myelomaThe European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...
EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...
LONDON, UK I 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 ...
Q3 2024 Earnings Call Transcript November 14, 2024 Emily Bodnar – H.C. Wainwright: Operator: Thank you for standing by. I ...
Circulating tumor cell (CTC) count can help inform treatment decisions for patients with cancer, including which patients are ...
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback